XDEMVY sales beat expectations, but heavier spending drove a sharp EPS miss

Sales came in ahead of the market’s bar. Q2 total revenue was $173.9 million versus published consensus of roughly $167.3 million, with product sales accounting for the entire quarter (Financial Highlights). XDEMVY sales therefore grew about 69% year over year, a solid commercial result against expectations.

The earnings conversion was materially worse than the sales headline suggests. GAAP loss per share was $0.43 versus a published expectation near $0.22 loss, as SG&A rose to $150.7 million from $103.0 million and R&D increased to $31.0 million from $15.6 million (Income Statement; SG&A expenses; R&D expenses). Commercial advertising, patient support, personnel, and pipeline spending absorbed most of the revenue upside, leaving the operating loss at $19.9 million despite the strong sales growth.

The underlying margin profile held, but profitability remains intentionally deferred. Gross margin was 93%, only modestly below 94% a year earlier (Cost of sales). The improvement in net loss versus $20.3 million last year was helped by $2.8 million of investment-exchange gains and $16.7 million of first-half China milestone revenue; neither meaningfully changes the recurring commercial profitability picture (Other income; License fees and collaboration revenue).

Pipeline expansion is strategically meaningful but adds execution and capital demands. Tarsus completed the iRenix acquisition and agreed to acquire Alkeus, adding a late-stage retina asset and a Phase 3 Stargardt program, while Calliope enrollment was completed and KORE continued toward first-half 2027 data (Recent business achievements). The filing does not provide the Alkeus transaction value or quantify its expected near-term financial impact, so the deal broadens the opportunity set but cannot yet be judged financially against consensus.

Net read: strong demand, offset by a clear earnings miss and higher investment intensity. First-half product sales reached $319.3 million, putting the business on track operationally against the previously stated $670–700 million 2026 XDEMVY sales range, but the filing excerpt does not state the updated annual guidance range, so any raise or cut cannot be assessed precisely (Financial Highlights; prior company guidance). The quarter is therefore better on revenue than expected, worse on per-share earnings, and broadly mixed overall rather than a clean beat.